Drug Trial Radar · NCT07167758
A Study Evaluating TRIV-509 in Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Aug 26, 2025
Primary completion
Oct 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Triveni BioIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.
Conditions
- Atopic Dermatitis
Interventions
TRIV-509Drug
TRIV-509 (Subcutaneous injection)
PlaceboDrug
Drug: Placebo (Matching Placebo subcutaneous injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with improvement of AD at Week 16Time frame: Baseline to Week 16
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Triveni Bio Site #11
Fountain Valley, California
Triveni Bio Site #4
San Diego, California
Triveni Bio Site #3
Miami, Florida
Triveni Bio Site #6
Indianapolis, Indiana
Triveni Bio Site #10
South Bend, Indiana
Triveni Bio Site #1
Camp Hill, Pennsylvania
Triveni Bio Site #16
Bellaire, Texas
Triveni Bio Site #5
Dallas, Texas
Triveni Bio Site #8
Spokane, Washington
Triveni Bio Site #38
Pleven, Bulgaria
Triveni Bio Site #39
Sofia, Bulgaria
Triveni Bio Site #13
Ajax, Ontario, Canada
Triveni Bio Site #17
Newmarket, Ontario, Canada
Triveni Bio Site #12
Niagara Falls, Ontario, Canada
Triveni Bio Site #15
North York, Ontario, Canada
Triveni Bio Site #22
Ostrava, Czechia
Triveni Bio Site #31
Pardubice, Czechia
Triveni Bio Site #21
Prague, Czechia
Triveni Bio Site #37
Prague, Czechia
Triveni Bio Site #23
Prague, Czechia
Triveni Bio Site #41
Budapest, Hungary
Triveni Bio Site #34
Budapest, Hungary
Triveni Bio Site #43
Debrecen, Hungary
Triveni Bio Site #29
Sosnowiec, Poland
Triveni Bio Site #33
Wroclaw, Lower Silesian Voivodeship, Poland
Triveni Bio Site #28
Warsaw, Masovian Voivodeship, Poland
Triveni Bio Site #24
Chorzów, Silesian Voivodeship, Poland
Triveni Bio Site #25
Katowice, Silesian Voivodeship, Poland
Triveni Bio Site #27
Katowice, Silesian Voivodeship, Poland
Triveni Bio Site #30
Poznan, Wielkopolska, Poland
Triveni Bio Site #26
Poznan, Wielkopolska, Poland
Triveni Bio Site #18
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.